

# Melissa J Labonte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2564265/publications.pdf>

Version: 2024-02-01

35  
papers

1,039  
citations

566801

15  
h-index

552369

26  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2493  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. <i>British Journal of Cancer</i> , 2012, 106, 1833-1841.	2.9	235
2	Molecular Pathways: Estrogen Pathway in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5842-5848.	3.2	181
3	Influence of Sex on the Survival of Patients With Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2265-2272.	0.8	112
4	The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1353-1364.	1.9	97
5	A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates. <i>Nucleic Acids Research</i> , 2011, 39, e112-e112.	6.5	75
6	Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase-Targeted Therapies in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 616-628.	1.9	44
7	Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 528-539.	1.9	37
8	PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy. <i>Oncotarget</i> , 2016, 7, 7885-7898.	0.8	33
9	Association of common gene variants in the WNT/ $\beta$ -catenin pathway with colon cancer recurrence. <i>Pharmacogenomics Journal</i> , 2014, 14, 142-150.	0.9	28
10	Assessing the in vivo efficacy of biologic antiangiogenic therapies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1-12.	1.1	22
11	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2261-2272.	1.9	19
12	Sustained inhibition of deacetylases is required for the antitumor activity of the histone deacetylase inhibitors panobinostat and vorinostat in models of colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 845-857.	1.2	18
13	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17808-17819.	3.3	18
14	The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic <i>BRAF</i> Mutant Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1280-1290.	1.9	17
15	The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. <i>Pharmacogenomics Journal</i> , 2014, 14, 130-134.	0.9	16
16	Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 226-234.	0.9	14
17	Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists. <i>Cell Death and Disease</i> , 2018, 9, 1081.	2.7	14
18	Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 38.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluorouracil chemotherapy. <i>Pharmacogenomics Journal</i> , 2014, 14, 135-141.	0.9	11
20	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	1.7	10
21	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. <i>NAR Cancer</i> , 2020, 2, zcaa012.	1.6	8
22	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2251-2258.	1.9	6
23	Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers. <i>Molecular Cancer Research</i> , 2022, 20, 841-853.	1.5	3
24	Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 528-535.	1.4	2
25	Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle. <i>Pharmacogenomics</i> , 2013, 14, 1671-1674.	0.6	2
26	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER $\pm$ -positive advanced breast cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 235-240.	0.9	2
27	Abstract 2670: Genetic variants in human epidermal growth factor receptor (HER) family gene predict tumor recurrence in breast cancer. , 2012, , .		1
28	Abstract 1526: Evaluation of the novel tumor suppressor gene, $\beta$ 2-Defensin-1, in colorectal cancer cell line models.. , 2013, , .		1
29	Abstract A087: Enzalutamide-induced hypoxia attenuates response and promotes resistance to enzalutamide in preclinical models of prostate cancer. <i>Cancer Research</i> , 2018, 78, A087-A087.	0.4	1
30	Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer. <i>Methods in Molecular Biology</i> , 2018, 1786, 195-206.	0.4	0
31	Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa062.	1.5	0
32	Predictive Markers in Colon Cancer. , 2013, , 1-23.		0
33	Abstract 4213: Evaluation of LMTK3 expression and tumor phenotype in estrogen-dependent colorectal cancer. , 2014, , .		0
34	Abstract 1811: Evaluation of anti-CXCR2 small molecule inhibitors as novel chemotherapy targeting the Interleukin-8 pathway in colorectal cancer. , 2014, , .		0
35	Abstract B035: Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis. , 2018, , .		0